Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Final Results From A Phase II Study Of Pemetrexed And Cisplatin With Concurrent Thoracic Radiation After Pem-Cis Induction In Patients With Unresectable Locally Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC).

P. Garrido, W. Engel-Riedel, M. Serke, P. Giraud, U. Ricardi, C. Vallejo, C. Visseren-Grul, S. Ameryckx, V. Soldatenkova, N. Chouaki, S. Novello
Published 2015 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
OBJECTIVES This single-arm multicenter Phase II study investigated the efficacy and safety of pemetrexed (Pem) and cisplatin (Cis) induction chemotherapy (CT) followed by full-dose Pem-Cis plus concurrent radiotherapy (RT) in patients with locally advanced non-squamous NSCLC. MATERIALS AND METHODS Patients with unresectable Stage III non-squamous NSCLC received two 21-day cycles of Pem 500 mg/m(2) (vitamin/folic acid supplementation and dexamethasone prophylaxis per Pem-label)+Cis 75 mg/m(2) on Day 1. Eligible patients who had not progressed continued with 2 further cycles of full-dose Pem-Cis plus concurrent RT (2 Gy/fraction, 5 days/week, 66 Gy total). Primary endpoint was the 1-year progression-free survival (PFS) rate. RESULTS Of 90 patients enrolled (all treated; median age 61 years, male/female 57%/43%, ECOG performance status 0/1 66%/34%, adenocarcinoma 90%, Stage III 36%/62%), 75 (83%) completed induction CT and started concurrent CT+RT. 64 (71%) patients received all 4 CT cycles and an RT dose ≥60 Gy. The 1-year PFS rate was 51.3% (95%CI: 42.0, 60.5). Median PFS was 10.6 months (95%CI: 8.6, 17.3), median OS was 26.2 months (95%CI: 16.7, not estimable). One patient died from enteritis (treatment-related) during Cycle 4. Four patients discontinued due to treatment-related adverse events, 1 on induction CT (renal failure), 3 on concurrent CT+RT (1 hypoacusis, 2 acute esophagitis). During induction CT, 18.9% of patients reported Grade 3/4 CTCAEs, only neutropenia (2.2%) and syncope (2.2%) were reported by >1 patient. During concurrent CT+RT, 41.3% of patients reported G3/4 CTCAEs, mainly esophagitis (12.0%), neutropenia (10.7%), and leukopenia (9.3%). CONCLUSION In this study of Pem-Cis induction CT followed by full-dose Pem-Cis with concurrent RT, median PFS was 10.6 months and toxicity was manageable, in line with previous data on Pem-Cis plus RT.
This paper references
10.1093/annonc/mdt241
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J. Vansteenkiste (2013)
10.1016/j.ijrobp.2010.01.014
Phase I trial of radiation with concurrent and consolidation pemetrexed and cisplatin in patients with unresectable stage IIIA/B non-small-cell lung cancer.
A. Brade (2011)
10.2307/2533471
Modelling Survival Data in Medical Research
D. Collett (1994)
10.1097/JTO.0b013e3182156109
Phase II Study of Pemetrexed and Cisplatin, with Chest Radiotherapy Followed by Docetaxel in Patients with Stage III Non-small Cell Lung Cancer
S. Gadgeel (2011)
Modelling Survival Data in Medical Research (2nd ed.) (Book)
M. K. Cowles (2004)
10.1200/JCO.2010.28.15_SUPPL.7082
Ongoing phase II study of pemetrexed plus carboplatin or cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/b non-small cell lung cancer: Interim update.
H. Choy (2010)
10.3322/caac.20138
Cancer statistics, 2012
R. Siegel (2012)
10.1200/JCO.2009.25.5489
Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
H. Tang (2010)
10.1016/j.lungcan.2014.07.005
Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.
G. Scagliotti (2014)
10.1200/JCO.2006.07.3569
Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.
E. Vokes (2007)
10.1097/JTO.0b013e3182a02546
Phase 2 Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin with Concurrent Radiation Therapy Followed by Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage IIIA/B Non–Small-Cell Lung Cancer
H. Choy (2013)
10.1080/00031305.1996.10473544
A COMPARISON OF APPROXIMATE INTERVAL ESTIMATORS FOR THE BERNOULLI PARAMETER
Lawrence M Leemis (1993)
10.1016/j.lungcan.2012.12.007
Phase I study of pemetrexed and cisplatin with concurrent high-dose thoracic radiation after induction chemotherapy in patients with unresectable locally advanced non-small cell lung cancer.
F. Mornex (2013)
10.1097/01.JTO.0000283090.56099.AF
Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone for unresectable stage III non-small cell lung cancer (NSCLC): randomized phase III trial: A1-01
M. K. Kim (2007)
10.1007/978-1-4612-4380-9_25
Nonparametric Estimation from Incomplete Observations
E. L. Kaplan (1958)
10.1200/JCO.2007.15.0375
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
G. Scagliotti (2008)
10.1097/JTO.0b013e318200f47e
Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced Non-small Cell Lung Cancer: The GFPC 05-03 Study
R. Descourt (2011)
10.1016/j.lungcan.2013.03.009
Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer Group 0008 study.
P. Garrido (2013)
10.1093/jnci/djr325
Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.
W. Curran (2011)
10.1007/978-1-4757-3656-4
AJCC Cancer Staging Manual
M. B. Amin (2002)
10.1093/jnci/92.3.205
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)
10.1200/JCO.2006.24.18_SUPPL.7048
Induction (ICT) or consolidation chemotherapy (CT) with cisplatin (C) and paclitaxel (P) plus concurrent chemo-radiation (CT/TRT) with cisplatin and vinorelbine (V) for unresectable non-small cell lung cancer (NSCLC) patients (pts): Randomized phase II trial GFPC-GLOT-IFCT 02-01.
P. Fournel (2006)
AJCC Cancer Staging Manual. 6th ed
F. Greene (2002)
10.1200/JCO.2009.26.2543
Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.
A. Aupérin (2010)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar